Username:   Password:

TECHNOLOGY | HEALTH | CONSUMER | INDUSTRIAL | FINANCIAL | NATURAL | INVESTING

Company Interview Excerpt
PAUL FREIMAN - NEUROBIOLOGICAL TECHNOLOGIES INC (NTII)
Full article published: 10/12/2001    


For Subscribers

Get this article online now!

Order just this article

Get Financial Filings and Annual Reports for Companies featured on TWST from EasyReports.net

TWST: Can we start out with a history and overview of the company?
Mr. Freiman: Neurobiological Technologies (NTI) was founded in 1987 by some research scientists in San Francisco who focused on the area of brain neurobiology. They had seen so much good work going on in academia amongst their colleagues around the world, and many were frustrated by a lack of funding from various governments at that particular point in time. They said if they could raise enough money to start a company, they would try to license products into the company, develop them, and then license them out to large pharmaceutical companies, as a template. The company succeeded in-licensing four products, of which two still exist. There were a lot of machinations that went on because of inexperience in the history of the company that eventually caused the company to go public, probably prematurely, in 1994 at about 8 a share. In 1995 NTI went out for a second round of financing at about 3 a share. The stock kept going down during that period of time, much of it due to a lack of experience in drug development. If you're going to develop medicines, you have to dance the ballet that the FDA sets out for you.

TWST: I gather the ballet has gotten more difficult recently.
Mr. Freiman: You know the rules; you follow the steps, and if you want to be innovative, you are probably going to get killed. So at any rate, we wasted a lot of time. In 1997, the company changed when I arrived. I had a lot of experience running a very large pharmaceutical company called Syntex. I had retired and then unretired to become an interim president of NTI. What we have done since that period of time is develop our lead compound to the point of approaching a new drug application (NDA) to the Food and Drug Administration (FDA) within three or four months. We husbanded money. The company's burn rate has gone from 9 million to 3 million annually. We have eight employees in the company now. I work with a group of consultants and contractors who I have worked with throughout my years in the industry. We pay them by the hour, or by the day, or by the week instead of having a lot of people sitting around. The employees whom we have now are really excellent, hardworking and faithful.

Tickers included in this excerpt: NTII

Have TWST notes emailed to you free:
Email address:


For more information call (212) 952 7400. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.

 

Why TWST?

Money Managers:

Thousands of easy-to-read verbatim CEO interviews
Must-have backgrounder before meeting with management
Analyst interviews offer discurse complement to published research
Roundtables 2-6 analysts discuss sector from multi-broker perspective
Fellow money managers discuss investment strategy and holdings.

Company Research:

Peer company research
Strategic planning and partnership information
Find out what Wall Street is saying about your company's sector and its competitors
Tool for sales and marketing teams to learn customer needs

Business Schools:

Unique tool for investment clubs
Background for finance, securities analysis and strategic planning classes
Placement resource for researching potential employers
Company research
Market intelligence

Consultants, Bankers & Corporate Advisors:

Quick background study on all major business sectors
Learn about potential client needs
Research tool for serving current clients

 

 

  HOME ABOUT TWST PRODUCTS SUBSCRIBE ADVANCED SEARCH SUBSCRIBER HOMEPAGE CONTACT